| However, amongst other resistors, the financial crisis | | | | Overview |
| resulted in reduced funding available for biotech | | | | Infrastructure and local regulations |
| companies. This fully updated CRO Market Outlook | | | | Benefits of outsourcing to China |
| assesses the market drivers and resistors and | | | | Challenges of outsourcing to China |
| predicts the effects of these. The report analyzes the | | | | Competitive dynamics |
| overarching trends in the industry; examines which | | | | The CRO market in India |
| regions are set to see growth in CRO activity; | | | | Overview |
| evaluates the leading CROs; and outlines the future of | | | | Infrastructure and local regulations |
| the industry. The report provides insight into conditions | | | | Intellectual property |
| into seven emerging regions including China, India and | | | | Legislative reforms |
| Latin America. It highlights the evolving business and | | | | Benefits of outsourcing to India |
| relationship models between CROs and sponsor | | | | Challenges of outsourcing to India |
| companies and enables optimal outsourcing strategy. | | | | Competitive dynamics |
| Key features of this report | | | | The CRO market in Latin America |
| Identifies and analyses the most recent trends and | | | | Overview |
| issues in outsourcing clinical R&D | | | | Infrastructure and local regulations |
| Describes where clinical trials will be conducted in the | | | | Argentina |
| future | | | | Brazil |
| Explores the complexities and the costs of outsourcing | | | | Mexico |
| R&D to different world regions | | | | Benefits of outsourcing to Latin America |
| Profiles the major international CRO players | | | | Challenges of outsourcing to Latin America |
| Provides a detailed assessment of the current CRO | | | | Competitive dynamics |
| market including market share information and the size | | | | The CRO markets in South Korea and Turkey |
| growth of R&D spending | | | | Overview |
| Focuses on emerging CRO markets | | | | Infrastructure and local regulations |
| Highlights evolving strategies for working with CROs | | | | Benefits of outsourcing to South Korea |
| Examines existing and future CRO business models | | | | Challenges of outsourcing to South Korea |
| Key findings from this report | | | | Benefits of outsourcing to Turkey |
| The total CRO market size is estimated at $20bn in | | | | Challenges of outsourcing to Turkey |
| 2008 and expected to grow at an annual rate of 8.5% | | | | Competitive dynamics |
| to reach $35bn through 2015. The market is highly | | | | Chapter 5 Leading players in the global CRO market |
| fragmented and the number of CROs worldwide has | | | | Summary |
| reached over 1,100 despite continued consolidation. | | | | Introduction |
| CROs provide substantial global capacity to drug | | | | The client perspective |
| developers and have become a critical contributor to | | | | Capabilities of leading CROs |
| clinical trial activity. Projects with high CRO involvement | | | | Quintiles Transnational Corp |
| are associated with shorter development times. | | | | Company profile |
| Of the large, global contract research providers, | | | | Business description |
| Quintiles is market leader, with 15% of the global | | | | Partnering collaborations and recent deals |
| market share, followed by Covance and PPD. The | | | | Covance |
| five largest CROs have increased their market share | | | | Company profile |
| and now hold 55% of the total market. | | | | Business description |
| The leading CROs are commodity full service | | | | Partnering collaborations and recent deals |
| providers operating on a global scale. They act as | | | | PPD Inc. |
| one-stop shops for all services, from preclinical through | | | | Company profile |
| marketing. | | | | Business description |
| The number of clinical studies conducted in Asia, | | | | Partnering collaborations and recent deals |
| Central and Eastern Europe and Latin America is | | | | Charles River Laboratories |
| constantly rising. India and China are the future | | | | Company Profile |
| outsourcing destinations of choice. | | | | Business description |
| CROs and pharmaceutical companies are turning to | | | | Partnering collaborations and recent deals |
| strategic partnerships to gain a competitive edge in the | | | | PAREXEL International |
| global business environment. | | | | Company profile |
| | | | | Business description |
| | | | | Partnering collaborations and recent deals |
| Table of Contents : | | | | ICON plc. |
| Executive summary | | | | Company profile |
| The global contract research organization market | | | | Business description |
| CRO market analysis | | | | Partnering collaborations and recent deals |
| Established regions in the global CRO market | | | | MDS Inc |
| Emerging regions in the global CRO market | | | | Company profile |
| Leading players in the global CRO market | | | | Business description |
| The future of contract research | | | | Partnering collaborations and recent deals |
| Chapter 1 The global contract research organization | | | | Kendle International |
| market | | | | Company profile |
| Summary | | | | Business description |
| Introduction | | | | Partnering collaborations and recent deals |
| The CRO contribution to drug development | | | | PRA International |
| Market overview | | | | Company profile |
| Key market drivers | | | | Business description |
| Key market restraints | | | | Partnering collaborations and recent deals |
| Conclusions and key findings | | | | PharmaNet Development Group |
| Overview of the global CRO market | | | | Company profile |
| Total revenue forecasts | | | | Business description |
| Global R&D expenditure and CRO market size | | | | Partnering collaborations and recent deals |
| Global clinical development outsourcing | | | | Chapter 6 The future of contract research |
| The contribution of CRO to drug development | | | | Summary |
| Current market drivers | | | | Introduction |
| Growth of R&D expenditure from biotech and | | | | The shift towards a strategic model |
| pharma | | | | Emerging markets |
| Cost pressures encourage R&D outsourcing | | | | Phases I and IV growth activity |
| Long term growth and R&D expenditure of | | | | Electronic data capture |
| biotechnology companies | | | | Biomarkers |
| Growing regulatory burden and safety concerns | | | | Selected acquisitions/partnerships |
| US | | | | Conclusion |
| EU | | | | Key findings and conclusions |
| Patient recruitment | | | | Chapter 7 Appendix |
| Increasing number of products in development | | | | Selected bibliography |
| The development of biomarkers | | | | Index |
| Current market restraints | | | | List of Figures |
| Near term reductions in biotech R&D spending | | | | Figure 1.1: Estimated CRO market ($bn), 2003-2015e |
| Growing competition and customer consolidation | | | | Figure 1.2: Global development expenditure and CRO |
| New financial realities alter biopharmaceutical | | | | market forecast ($bn), 2008-2014e |
| outsourcing landscape | | | | Figure 1.3: CRO usage and number of days by which |
| Shortage of clinical research personnel | | | | projects overrun |
| Electronic data capture: a threat to CRO revenue | | | | Figure 1.4: Global pharmaceutical R&D expenditure |
| Key market trends | | | | ($bn), 2000-2014e |
| Globalization | | | | Figure 1.5: Number of FDA approvals 1990-2008 |
| EDC evolution | | | | Figure 1.6: Comparison of drug development cost |
| Strategic alliances | | | | estimates |
| Chapter 2 CRO market analysis | | | | Figure 1.7: Global biotech R&D expenditure ($bn), |
| Summary | | | | 2004-2012e |
| Introduction | | | | Figure 1.8: Number of products in development by |
| Market conditions | | | | phase 1998-2009 |
| Competitive analysis | | | | Figure 1.9: CRO/Sponsor relationship models |
| Market share analysis | | | | Figure 2.10: Market share of major players, 2008 |
| Competitive dynamics | | | | Figure 2.11: Typical full service CRO model |
| Academic medical centers | | | | Figure 3.12: R&D expenditures of PhRMA |
| Site management organizations | | | | members and non-member companies ($bn), 1980- |
| Laboratory analytical services | | | | 2009 |
| Non-CRO niche service providers | | | | Figure 3.13: Overall indexed clinical trial costs by region, |
| Conclusion | | | | 2006-2008 |
| CRO service models | | | | Figure 3.14: The European CRO market - revenue |
| Introduction | | | | forecast ($bn), 2008-2012e |
| The full service model | | | | Figure 3.15: Pharmaceutical R&D expenditure in |
| SWOT analysis | | | | Europe ($bn), 1990-2008 |
| The niche model | | | | Figure 4.16: Geographic distribution of clinical trials, 2005 |
| SWOT analysis | | | | to 2009f |
| Industry strategies | | | | Figure 4.17: Clinical trial costs of European countries |
| Consolidation: Mergers & acquisitions in the CRO | | | | compared to the UK |
| industry | | | | Figure 4.18: Comparison of trial registration periods in |
| Expanding the continuum of services: vertical | | | | CEE countries (days) |
| integration | | | | Figure 4.19: CRO market in China ($m), 2007-2012e |
| Forward integration | | | | Figure 4.20: China's capabilities across the value chain |
| Backward integration | | | | Figure 4.21: India's capabilities across the value chain |
| Industry challenges | | | | Figure 4.22: Number of clinical trials in Latin America, |
| Consolidation within the CRO industry: a threat to close | | | | 2000-2008 |
| customer relationships | | | | Figure 4.23: Clinical trials in South Korea, 2005-2009e |
| Strategic outsourcing: demonstrating clear value to | | | | Figure 5.24: Revenue growth of top public CROs in |
| clients | | | | 2007-2008 |
| Co-development: sharing the risk | | | | Figure 5.25: Capabilities of leading CROs, 2009 |
| Chapter 3 Established regions in the global CRO | | | | Figure 6.26: Regional presence of major CROs |
| market | | | | Figure 6.27: Attractiveness of selected countries for |
| Summary | | | | clinical trials |
| Introduction | | | | Figure 6.28: Global numbers of phase IV trials |
| The US CRO market | | | | 2006-2009e |
| Overview | | | | Figure 6.29: Electronic data capture market size ($m), |
| Drivers of the US CRO market | | | | 2006E-2012e |
| Challenges of the US CRO market | | | | Figure 6.30: Clinical trials using predictive biomarkers, |
| Competitive dynamics | | | | 2005-2009 |
| The CRO market in Western Europe | | | | List of Tables |
| Overview | | | | Table 1.1: Functions commonly performed by CROs |
| Infrastructure and local regulations | | | | Table 2.2: The global R&D outsourcing market: |
| Drivers of the CRO market in Western Europe | | | | five major segments |
| Challenges of the CRO market in Western Europe | | | | Table 2.3: SWOT analysis: the full service model |
| Competitive dynamics | | | | Table 2.4: SWOT analysis: the niche model |
| Chapter 4 Emerging regions in the global CRO market | | | | Table 2.5: Key deals in the CRO sector |
| Summary | | | | Table 4.6: Major CROs operating in Eastern Europe, |
| Introduction | | | | 2009 |
| The Central and Eastern European CRO market | | | | Table 4.7: Domestic Chinese CROs |
| Overview | | | | Table 4.8: Major domestic CROs operating in Latin |
| Infrastructure and local regulations | | | | America, 2009 |
| Benefits of outsourcing to CEE | | | | Table 4.9: Selected domestic CROs in South Korea |
| Challenges of outsourcing to CEE | | | | and Turkey |
| Competitive dynamics | | | | Table 5. |
| The CRO market in China | | | | |